WO1998032451A9 - Traitement des maladies auto-immunes a l'aide d'une tolerance induite en combinaison avec du methotrexate - Google Patents
Traitement des maladies auto-immunes a l'aide d'une tolerance induite en combinaison avec du methotrexateInfo
- Publication number
- WO1998032451A9 WO1998032451A9 PCT/US1998/001648 US9801648W WO9832451A9 WO 1998032451 A9 WO1998032451 A9 WO 1998032451A9 US 9801648 W US9801648 W US 9801648W WO 9832451 A9 WO9832451 A9 WO 9832451A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methotrexate
- disease
- autoimmune
- antigen
- combination
- Prior art date
Links
- 229960000485 methotrexate Drugs 0.000 title claims abstract description 145
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 title claims abstract description 144
- 206010003816 Autoimmune disease Diseases 0.000 title claims abstract description 59
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 title claims abstract description 43
- 239000000427 antigen Substances 0.000 claims abstract description 102
- 102000038129 antigens Human genes 0.000 claims abstract description 99
- 108091007172 antigens Proteins 0.000 claims abstract description 99
- 230000000981 bystander Effects 0.000 claims abstract description 82
- 239000000203 mixture Substances 0.000 claims abstract description 68
- 230000001363 autoimmune Effects 0.000 claims abstract description 55
- 230000004044 response Effects 0.000 claims abstract description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 230000001629 suppression Effects 0.000 claims description 83
- 201000010099 disease Diseases 0.000 claims description 53
- 229920001436 collagen Polymers 0.000 claims description 41
- 102000008186 Collagen Human genes 0.000 claims description 40
- 108010035532 Collagen Proteins 0.000 claims description 40
- 229960005188 collagen Drugs 0.000 claims description 40
- 102000015528 Myelin Basic Protein Human genes 0.000 claims description 39
- 108010025255 Myelin Basic Protein Proteins 0.000 claims description 39
- 201000006417 multiple sclerosis Diseases 0.000 claims description 22
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims description 18
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 13
- 206010012601 Diabetes mellitus Diseases 0.000 claims description 11
- 230000001404 mediated Effects 0.000 claims description 10
- 108060003199 Glucagon Proteins 0.000 claims description 8
- 229960004666 Glucagon Drugs 0.000 claims description 8
- MASNOZXLGMXCHN-ZLPAWPGGSA-N Glucagonum Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 8
- 241000283690 Bos taurus Species 0.000 claims description 6
- 102000004877 Insulin Human genes 0.000 claims description 6
- 108090001061 Insulin Proteins 0.000 claims description 6
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims description 5
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims description 5
- 101710040745 B19R Proteins 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 206010028417 Myasthenia gravis Diseases 0.000 claims description 3
- 102000016202 Proteolipids Human genes 0.000 claims description 3
- 108010010974 Proteolipids Proteins 0.000 claims description 3
- 102000012422 Collagen Type I Human genes 0.000 claims description 2
- 108010022452 Collagen Type I Proteins 0.000 claims description 2
- 102000017099 Myelin-Associated Glycoprotein Human genes 0.000 claims 2
- 108010013731 Myelin-Associated Glycoprotein Proteins 0.000 claims 2
- 102000002233 Myelin-Oligodendrocyte Glycoprotein Human genes 0.000 claims 2
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 claims 2
- 102000008214 Glutamate decarboxylases Human genes 0.000 claims 1
- 108091022086 Glutamate decarboxylases Proteins 0.000 claims 1
- 102000034433 acetylcholine receptors Human genes 0.000 claims 1
- 108020000715 acetylcholine receptors Proteins 0.000 claims 1
- 102000021234 retinoid binding proteins Human genes 0.000 claims 1
- 108091010221 retinoid binding proteins Proteins 0.000 claims 1
- 230000035492 administration Effects 0.000 description 52
- 210000004027 cells Anatomy 0.000 description 47
- 241000700159 Rattus Species 0.000 description 37
- 210000001519 tissues Anatomy 0.000 description 29
- 230000000694 effects Effects 0.000 description 28
- 210000001744 T-Lymphocytes Anatomy 0.000 description 26
- 201000002491 encephalomyelitis Diseases 0.000 description 22
- 241000124008 Mammalia Species 0.000 description 19
- 102000004388 Interleukin-4 Human genes 0.000 description 18
- 108090000978 Interleukin-4 Proteins 0.000 description 18
- 229940028885 Interleukin-4 Drugs 0.000 description 18
- 108090000174 Interleukin-10 Proteins 0.000 description 16
- 102000003814 Interleukin-10 Human genes 0.000 description 16
- 229940076144 Interleukin-10 Drugs 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 15
- 206010003246 Arthritis Diseases 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- 241000282412 Homo Species 0.000 description 13
- 241000282414 Homo sapiens Species 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 238000010171 animal model Methods 0.000 description 12
- 210000000056 organs Anatomy 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 102000004127 Cytokines Human genes 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 230000035611 feeding Effects 0.000 description 11
- 230000004957 immunoregulator effect Effects 0.000 description 11
- 206010023232 Joint swelling Diseases 0.000 description 8
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 8
- 239000000443 aerosol Substances 0.000 description 8
- 230000028993 immune response Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 210000000987 Immune System Anatomy 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 7
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 7
- 238000004166 bioassay Methods 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 230000000534 elicitor Effects 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 230000001506 immunosuppresive Effects 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 206010038001 Rebound effect Diseases 0.000 description 6
- 230000000240 adjuvant Effects 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000001965 increased Effects 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 230000001739 rebound effect Effects 0.000 description 6
- 210000004369 Blood Anatomy 0.000 description 5
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 5
- 102000002227 Interferon Type I Human genes 0.000 description 5
- 108010014726 Interferon Type I Proteins 0.000 description 5
- 210000000952 Spleen Anatomy 0.000 description 5
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N Tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 230000000670 limiting Effects 0.000 description 5
- 230000000051 modifying Effects 0.000 description 5
- 230000001105 regulatory Effects 0.000 description 5
- 210000003289 regulatory T cell Anatomy 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000700199 Cavia porcellus Species 0.000 description 4
- 102000000503 Collagen Type II Human genes 0.000 description 4
- 108010041390 Collagen Type II Proteins 0.000 description 4
- 102100016020 IFNG Human genes 0.000 description 4
- 101700086956 IFNG Proteins 0.000 description 4
- 206010033799 Paralysis Diseases 0.000 description 4
- 101700025296 RBP3 Proteins 0.000 description 4
- 102100016799 RBP3 Human genes 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 102000004965 antibodies Human genes 0.000 description 4
- 108090001123 antibodies Proteins 0.000 description 4
- 230000000890 antigenic Effects 0.000 description 4
- 230000002917 arthritic Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000002609 media Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000002588 toxic Effects 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 208000005783 Autoimmune Thyroiditis Diseases 0.000 description 3
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 3
- 210000004556 Brain Anatomy 0.000 description 3
- 210000003414 Extremities Anatomy 0.000 description 3
- 210000004837 Gut-associated lymphoid tissue Anatomy 0.000 description 3
- 206010062016 Immunosuppression Diseases 0.000 description 3
- 210000004072 Lung Anatomy 0.000 description 3
- 210000003563 Lymphoid Tissue Anatomy 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 239000007975 buffered saline Substances 0.000 description 3
- 230000001186 cumulative Effects 0.000 description 3
- 229940079593 drugs Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000002708 enhancing Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 description 3
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N 2-mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 108009000283 Allograft Rejection Proteins 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- FBOZXECLQNJBKD-CYBMUJFWSA-N D-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-CYBMUJFWSA-N 0.000 description 2
- JZUFKLXOESDKRF-UHFFFAOYSA-N Dichlothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 210000002683 Foot Anatomy 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 210000004153 Islets of Langerhans Anatomy 0.000 description 2
- 210000001503 Joints Anatomy 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 210000003141 Lower Extremity Anatomy 0.000 description 2
- 229940071648 Metered Dose Inhaler Drugs 0.000 description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 2
- 229940010383 Mycobacterium tuberculosis Drugs 0.000 description 2
- 241000772415 Neovison vison Species 0.000 description 2
- 210000002966 Serum Anatomy 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003190 augmentative Effects 0.000 description 2
- 230000001580 bacterial Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 210000002919 epithelial cells Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003203 everyday Effects 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000002519 immonomodulatory Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000003902 lesions Effects 0.000 description 2
- GZQKNULLWNGMCW-PWQABINMSA-J lipid A(4-) Chemical compound O1[C@H](CO)[C@@H](OP([O-])([O-])=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP([O-])([O-])=O)O1 GZQKNULLWNGMCW-PWQABINMSA-J 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000006201 parenteral dosage form Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002035 prolonged Effects 0.000 description 2
- 230000036647 reaction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000002522 swelling Effects 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229940035676 ANALGESICS Drugs 0.000 description 1
- 102000003852 Autoantibodies Human genes 0.000 description 1
- 108090000206 Autoantibodies Proteins 0.000 description 1
- 210000003719 B-Lymphocytes Anatomy 0.000 description 1
- 210000001175 Cerebrospinal Fluid Anatomy 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 206010011953 Decreased activity Diseases 0.000 description 1
- 208000004275 Demyelinating Disease Diseases 0.000 description 1
- 229940112141 Dry Powder Inhaler Drugs 0.000 description 1
- 208000000999 Encephalomyelitis, Autoimmune, Experimental Diseases 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018075 Generalised anxiety disease Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102100015720 IFNB1 Human genes 0.000 description 1
- 101700011451 IFNB1 Proteins 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 208000007903 Liver Failure Diseases 0.000 description 1
- 210000001165 Lymph Nodes Anatomy 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 210000004248 Oligodendroglia Anatomy 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 210000000496 Pancreas Anatomy 0.000 description 1
- 206010033885 Paraparesis Diseases 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- 229940049954 Penicillin Drugs 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 210000001986 Peyer's Patches Anatomy 0.000 description 1
- 210000000173 Precursor Cells, T-Lymphoid Anatomy 0.000 description 1
- 206010037714 Quadriplegia Diseases 0.000 description 1
- 239000007759 RPMI Media 1640 Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010038435 Renal failure Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039447 Salmonellosis Diseases 0.000 description 1
- 210000000273 Spinal Nerve Roots Anatomy 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241001222723 Sterna Species 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- 229960005322 Streptomycin Drugs 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 210000003283 T-Lymphocytes, Helper-Inducer Anatomy 0.000 description 1
- 210000004241 Th2 Cells Anatomy 0.000 description 1
- HWKQNAWCHQMZHK-UHFFFAOYSA-N Trolnitrate Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O HWKQNAWCHQMZHK-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002730 additional Effects 0.000 description 1
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 1
- 230000000202 analgesic Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 229960000626 benzylpenicillin Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002354 daily Effects 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 230000001066 destructive Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 108060003523 dnaK Proteins 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 230000001712 encephalitogenic Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000003090 exacerbative Effects 0.000 description 1
- 239000011152 fibreglass Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001976 improved Effects 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 200000000018 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000007798 limiting dilution analysis Methods 0.000 description 1
- 230000001926 lymphatic Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000004962 mammalian cells Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 102000005614 monoclonal antibodies Human genes 0.000 description 1
- 108010045030 monoclonal antibodies Proteins 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- -1 myelin Proteins 0.000 description 1
- 201000002481 myositis Diseases 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000001537 neural Effects 0.000 description 1
- 230000000926 neurological Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 244000052769 pathogens Species 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000001175 peptic Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000003449 preventive Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive Effects 0.000 description 1
- 230000002062 proliferating Effects 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 230000002207 retinal Effects 0.000 description 1
- 235000020945 retinal Nutrition 0.000 description 1
- 239000011604 retinal Substances 0.000 description 1
- 230000001177 retroviral Effects 0.000 description 1
- 238000009288 screen filtration Methods 0.000 description 1
- 230000003248 secreting Effects 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000003393 splenic Effects 0.000 description 1
- 230000002269 spontaneous Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 230000001960 triggered Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000001755 vocal Effects 0.000 description 1
Definitions
- This invention pertains to the field of treatment of autoimmune diseases by tolerization. This invention also relates to the field of treatment of autoimmune diseases by administration of methotrexate.
- Autoimmune diseases are characterized by an abnormal immune response directed against normal autologous (self) tissues.
- autoimmune diseases in mammals can generally be classified in one of two different categories: cell-mediated (i.e. , T-cell-mediated) or antibody-mediated (i.e. , -cell mediated) disorders.
- T-cell-mediated autoimmune diseases include multiple sclerosis (MS), rheumatoid arthritis (RA), the autoimmune stage of diabetes mellitus (juvenile-onset or Type 1 diabetes) and autoimmune uveoretinitis (AUR).
- Antibody-mediated autoimmune diseases include without limitation myasthenia gravis (MG) , autoimmune thyroid- itis (AT), and systemic lupus erythematosus (SLE).
- autoimmune diseases are currently being treated with drugs that suppress immune responses systemicaUy in a non-specific manner, i.e., drugs incapable of selectively suppressing the abnormal immune response.
- drugs that suppress immune responses systemicaUy in a non-specific manner
- drugs incapable of selectively suppressing the abnormal immune response.
- One such drug is methotrexate, a biological response modifier that selectively inhibits fast growing cells.
- methotrexate has significant toxic and other side effects and eventually induces "global" immunosuppression in the subject being treated.
- prolonged treatment with a normal course of methotrexate downregulates the normal protective immune response against pathogens, thereby increasing the risk of infection.
- patients subjected to prolonged global immunosuppression have an increased risk of developing severe medical complications from the treatment, such as malignancies, liver, and kidney failure.
- methotrexate is normally administered once a week in a high dose of, e.g., 7.5 to 25 mg. Such treatment is commonly used to treat rheumatoid arthritis, and has been effectively used to treat multiple sclerosis (Goodkin et al., Ann. Neurology. 37:30, 1995). Although oral administration is most common, methotrexate is also commercially available for parenteral administration for such treatment.
- Intravenous administration of autoantigens has been found to induce immune suppression through a mechanism called clonal anergy.
- Clonal anergy causes deactivation of only immune attack T-cells specific to a particular antigen, the result being a significant reduction in the immune response to this antigen.
- the autoimmune response-promoting T-cells specific to an autoantigen once anergized, no longer proliferate in response to that antigen.
- This reduction in proliferation also reduces the immune reactions responsible for autoimmune disease symptoms (such as neural tissue damage that is observed in MS).
- oral administration of autoantigens (or immunodominant fragments) in a single dose and in substantially larger amounts than those that trigger "active suppression” may also induce tolerance through anergy (or clonal deletion).
- a method of treatment has also been disclosed that proceeds by active suppression. Active suppression functions via a different mechanism from that of clonal anergy. This method, discussed extensively in PCT Application PCT/US93/01705, involves oral or mucosal administration of antigens specific to the tissue under autoimmune attack. These are called “bystander antigens” and are defined below.
- This treatment causes regulatory (suppressor) T-cells to be induced in the gut-associated lymphoid tissue (GALT), or bronchial associated lymphoid tissue (BALT), or most generally, mucosa associated lymphoid tissue (MALT) (MALT includes GALT and BALT).
- T-cells elicited by the bystander antigen are targeted to the locus of autoimmune attack where they mediate the local release of certain immunomodulatory factors and cytokines, such as transforming growth factor beta (TGF- ⁇ ), interleukin-4 (IL-4), and/or interleukin-10 (IL- 10).
- TGF- ⁇ transforming growth factor beta
- IL-4 interleukin-4
- IL-10 interleukin-10
- IL-4 and IL-10 are also antigen-nonspecific immunoregulatory cytokines.
- IL-4 in particular enhances Th2 response, i.e., acts on T-cell precursors and causes them to differentiate preferentially into Th2 cells at the expense of Thl responses.
- IL-4 also indirectly inhibits Thl exacerbation.
- IL-10 is a direct inhibitor of Thl responses.
- Type I interferon or polypeptides having Type I interferon activity, either alone or in conjunction with oral or mucosal administration of autoantigens or bystander antigens, is beneficial in reducing the symptoms of autoimmune disease.
- Suboptimal doses of Type I ( ⁇ or ⁇ ) interferon potentiate the tolerizing effect of the autoantigens and bystander antigen.
- Type I interferon especially ⁇ -IFN, is known to have certain immunomodulatory properties, e.g. , inhibition of the activity of ⁇ -interferon (IFN- ⁇ ).
- IFN- ⁇ has been shown to exacerbate MS, and may be involved in the pathogenesis of MS lesions. Thus, IFN- ⁇ appears to have a beneficial effect due in part to its ability to inhibit IFN- ⁇ expression by T- cells.
- PCT/US95/04512 filed 04/07/95, describes use of Th2-enhancing cytokines in conjunction with oral tolerization employing autoantigens or bystanders antigens.
- One object of the invention is to allow administration of less toxic amounts of methotrexate in the treatment of autoimmune diseases.
- An additional object is to allow administration of methotrexate in more frequent administrations in order to reduce the amount that is administered at one time. Another object is to provide a treatment for autoimmune disease that is more effective than either administration of methotrexate alone or administration of an oral, or more generally, a mucosal tolerizing agent alone.
- the present invention relates to a method for treating autoimmune disease.
- the method involves mucosally administering a bystander antigen.
- the method also involves orally, enterally, or parenterally administering methotrexate.
- methotrexate The amounts of bystander antigen and methotrexate are effective in combination to suppress autoimmune response associated with the autoimmune disease.
- the present invention relates to a pharmaceutical combination for oral or enteral administration to treat autoimmune disease.
- the combination comprises methotrexate and a bystander antigen, the amounts of the bystander antigen and methotrexate being effective in combination to suppress autoimmune response associated with the autoimmune disease.
- the present invention relates to a method for treating autoimmune disease.
- the method involves mucosally administering an autoantigen.
- the method also involves orally, enterally, or parenterally administering methotrexate.
- the amounts of autoantigen and methotrexate are effective in combination to suppress autoimmune response associated with the disease.
- the present invention relates to a pharmaceutical combination for oral or enteral administration to treat autoimmune disease.
- the combination comprises methotrexate and an autoantigen, the amounts of the autoantigen and methotrexate being effective in combination to suppress autoimmune response associated with the autoimmune disease.
- Figure 1 is a graph that shows the effects on EAE clinical scores of administering optimal and sub-optimal dosages of methotrexate.
- Figure 2 is a graph that shows the effects on EAE clinical scores of administering either an optimal dose of methotrexate or a 1 mg dose of MBP.
- Figure 3 is a graph that shows the effects on EAE clinical scores of combining an optimal dose of methotrexate with MBP as compared to administering an optimal dose of methotrexate alone.
- Figure 4 is a graph showing the effects on EAE of administering a combination of a sub-optimal dose of 40 ⁇ g methotrexate and a 1 mg dose of MBP as compared with administering either alone.
- Figure 5 is a graph showing the effects on EAE of administering a combination of a sub-optimal dose of 20 ⁇ g methotrexate and a 1 mg dose of MBP as compared with admimstering either alone.
- Figure 6 is a graph showing the swollen joint count measured in rheumatoid arthritis patients who, beginning at week 8 of a clinical study, were administered either a combination of oral type ⁇ collagen and oral methotrexate (open diamonds) or only oral type ⁇ collagen (closed boxes).
- Figure 7 is a graph showing the tender joint count measured in rheumatoid arthritis patients who, beginning at week 8 of a clinical study, were administered either a combination of oral type ⁇ collagen and oral methotrexate (open diamonds) or only oral type ⁇ collagen (closed boxes).
- Figure 8 shows the percent of patients achieving cumulative Paulus 20 response for those administered either a combination of type ⁇ collagen and methotrexate, or type JJ collagen alone.
- the present invention allows a lower amount of methotrexate to be administered for treatment of autoimmune disease than would otherwise be necessary (a suboptimal dose). This is highly advantageous because of methotrexate' s high toxicity.
- the suppressive effect of administering a combination of methotrexate and MBP has been found to be more effective than the effect of administering either alone.
- Methotrexate has been found not to prevent treatment by mucosal tolerization, even though methotrexate is known to inhibit cell division, i.e. , it has not detrimentally affected the cells mediating treatment of autoimmune disease by tolerance. Furthermore, administration of tolerizing agent has been found not to interfere with methotrexate 's inhibitory effects.
- methotrexate in EAE rats and in humans, results in a rebound of disease following suppression (after the course of administrations is completed). Such a rebound is not observed with oral, or mucosal, tolerization.
- the combination of MBP and methotrexate does not result in a rebound effect.
- admimstering methotrexate does not interfere with this benefit of mucosal tolerization.
- methotrexate and tolerizing agent can be frequently administered at lower doses per administration. While methotrexate is normally administered once a week in a high dose to treat autoimmune disease, the combination of the invention has been found to be effective when administered three times a week at lower doses. As described above, admimstering an overall lower dose of methotrexate according to the invention acts to reduce toxicity. Administering that lower dose in subdivided form at intervals during the week further acts to reduce toxicity.
- methotrexate is normally admmistered by itself at an optimal dose of 10 mg per week to treat an autoimmune disease
- a suboptimal dose of 2 mg, three times a week can be administered with an effective amount of tolerizing agent.
- the invention can be viewed as an improvement on the treatment of autoimmune conditions with methotrexate, it can also be viewed as an improvement on the treatment of autoimmune diseases by oral (or mucosal) tolerization.
- “Bystander antigen” or “bystander” is a protein, protein fragment, peptide, glycoprotein, or any other immunogenic substance (i.e. a substance capable of eliciting an immune response) that (i) is, or is derived from, a component specific to the organ or tissue under autoimmune attack; and (ii) upon oral or enteral administration elicits regulatory (suppressor) T-cells (which can be of the CD4+ or CD8+ type) that cause at least one antigen-nonspecific immunosuppressive factor or immunoregulatory cytokine (such as TGF-/3, IL-4 or IL-10) to be released at the organ or tissue under attack and thereby suppress immune attack cells that contribute to autoimmune destruction.
- regulatory (suppressor) T-cells which can be of the CD4+ or CD8+ type
- immunoregulatory cytokine such as TGF-/3, IL-4 or IL-10
- the term includes but is not limited to autoantigens and fragments thereof involved in autoimmune attack.
- the term includes antigens normally not exposed to the immune system which become exposed in the locus of autoimmune attack as a result of autoimmune tissue destruction.
- An example is heatshock proteins, which although not specific to a particular tissue are normally shielded from contact with the immune system.
- “Bystander suppression” is suppression at the locus of autoimmune attack of cells that contribute to autoimmune destruction; this suppression is mediated by the release of one or more immunosuppressive factors (including Th2-enhancing cytokines and Thl- inhibiting cytokines) from suppressor T-cells elicited by the ingestion (or inhalation) of a bystander antigen and recruited to the site where cells contributing to autoimmune destruction are found. The result is antigen-nonspecific but locally restricted downregulation of the autoimmune responses responsible for tissue destruction.
- immunosuppressive factors including Th2-enhancing cytokines and Thl- inhibiting cytokines
- Autoimmune disease is defined herein as a spontaneous or induced malfiinc- tion of the immune system of mammals, including humans, in which the immune system fails to distinguish between foreign immunogenic substances within the mammal and/or autologous substances and, as a result, treats autologous tissues and substances as if they were foreign and mounts an immune response against them.
- the term includes human autoimmune diseases and animal models therefor.
- Autoantigen is any substance or a portion thereof normally found within a mammal that, in an autoimmune disease, becomes the primary (or a primary) target of attack by the immune system.
- the term also includes antigenic substances that induce conditions having the characteristics of an autoimmune disease when admmistered to mammals.
- the term includes peptic subclasses consisting essentially of immunodominant epitopes or immunodominant epitope regions of autoantigens.
- Immunodominant epitopes or regions in induced autoimmune conditions are fragments of an autoantigen that can be used instead of the entire autoantigen to induce the disease.
- immunodominant epitopes or regions are fragments of antigens specific to the tissue or organ under autoimmune attack and recognized by a substantial percentage (e.g. a majority though not necessarily an absolute majority) of autoimmune attack T- cells.
- Treatment is intended to include both prophylactic treatment to prevent or delay the onset of an autoimmune disease (or to prevent the manifestation of clinical or sub- clinical, e.g., histological, symptoms thereof), as well as therapeutic suppression or alleviation of symptoms after the manifestation of autoimmune disease, by abating autoimmune attack and preventing or slowing down autoimmune tissue destruction.
- “Abatement”, “suppression” or “reduction” of autoimmune attack or reaction encompasses partial reduction or amelioration of one or more symptoms of the attack or reaction.
- a “substantially” increased suppressive effect (or abatement or reduction) of autoimmune reaction means a significant decrease in one or more markers or histological or clinical indicators of autoimmune reaction or disease.
- Nonlimiting examples are a reduction by at least 1 unit in limb paralysis score or in arthritis score, a significant reduction in the frequency of autoreactive T-cells, and a reduction of at least about 0.5 units in insulitis scoring (measured, e.g., as described in Zhang et al., PNAS. 1991, 88:10252-10256).
- Oral administration includes oral, enteral or intragastric administration. By- inhalation administration also accomplishes a tolerizing effect in autoimmune disease.
- Parenteral administration includes subcutaneous, intradermal, intramuscular, intravenous, intraperitoneal or intrathecal administration.
- Administration "in conjunction with” encompasses simultaneous and sequential administration, as well as administration in combined form or separately.
- EAE Experimental autoimmune encephalomyelitis
- MBP myelin basic protein
- MOG myelin oligodendrocyte protein
- PLP proteolipid protein
- CFA Complete Freund's Adjuvant
- This treatment induces either a monophasic or an exacerbating/remitting form of demyelinating disease (depending on the type and species of rodent and well-known details of induction).
- the induced disease has many of the characteristics of the autoimmune disease MS and serves as an animal model therefor.
- the successful treatment of EAE by oral tolerization and the parallel success in decreasing the frequency of disease-inducing cells in humans, and, in many cases, ameliorating the symptoms of MS, using oral administration of myelin, validates the use of EAE as a model system for predicting the success of different oral tolerization regimens.
- Immunization with Mycobacterium tuberculosis or with CFA in oil into the dorsal root tail of susceptible mammals induces a disease used as a model for human rheumatoid arthritis.
- immunization with Type JJ collagen with an adjuvant will also induce a disease (collagen-induced arthritis or "CIA") that serves as a model for human rheumatoid arthritis.
- CIA collagen-induced arthritis
- suppression mediated by mucosal administration of bystander antigens is brought about by elicitation of targetable immunoregulatory T-cells that release one or more immunosuppressive factors, such as transforming growth factor-beta (TGF-jS); and/or Th2-enhancing cytokines, such as interleukin 4 (IL-4); and/ or interleukin 10 (IL-10) at the locus of the autoimmune attack.
- TGF-jS transforming growth factor-beta
- Th2-enhancing cytokines such as interleukin 4 (IL-4); and/ or interleukin 10 (IL-10) at the locus of the autoimmune attack.
- IL-4 interleukin 4
- IL-10 interleukin 10
- the immunoregulatory cytokines released by the elicited regulatory cells are antigen-nonspecific, even though these regulatory T-cells release (or induce the release of) immunoregulatory cytokines only when triggered by an antigenic determinant identical to one on the mucosally administered antigen.
- Recruitment of the immunoregulatory T-cells to a locus within a mammal where cells contributing to the autoimmune destruction of an organ or tissue are concentrated allows for the release of immunoregulatory substances in the vicinity of the autoimmune attack and suppresses all types of immune system cells responsible for such attack.
- the target for the suppressor T-cells is the organ or tissue under immune attack in the particular autoimmu e disease where the destructive cells are concentrated.
- the bystander antigen may be an autoantigen or a peptide containing an immunodominant epitope of an autoantigen.
- the bystander may be another tissue- specific antigen that is not an autoantigen; hence, the autoantigen (or autoantigens) involved in the particular disease being treated need not be identified.
- tissue-specific (bystander) antigen an example of the active suppression mechanism of bystander suppression for a tissue-specific (bystander) antigen is as follows: After a tissue-specific (bystander) antigen is administered orally (or enterally, i.e. , directly into the stomach) it passes into the small intestine, where it comes into contact with the Peyer's patches and villi, which are collections of a large number of immunocytes located under the intestinal wall. These cells, in turn, are in communication with the immune system, including the spleen and lymph nodes.
- suppressor (CD8+ or CD4+) T-cells are induced, released into the blood or lymphatic circulation, and then recruited to the area of autoimmune attack, where they cause the release of TGF-/3 and/or other immunoregulatory substances that downregulate the activated helper T-cells as well as the B-cells directed against the mammal's own tissues.
- Suppression induced in this manner is antigen-nonspecific.
- the resulting tolerance is specific for the particular autoimmune disease, i.e.
- the bystander antigen is specific for the tissue under attack and suppressor cells elicited by ingestion of the bystander antigen suppress the immune attack cells that are found at or near the tissue being damaged.
- Bystander antigens and autoantigens can be purified from natural sources (the tissue or organ where they normally occur) and can also be obtained using recombinant DNA technology, in bacterial, yeast, insect (e.g. baculovirus) and mammalian cells using techniques well-known to those of ordinary skill in the art.
- Amino acid sequences for many potential and actual bystander antigens are known: See, e.g., Hunt, C. et al PNAS (USA . 82:6455-6459, 1985 (heat shock protein hsp70); Burkhardt, H., et al., Eur. J. Immunol.
- IRBP IRBP
- bovine and mouse PLP The amino acid sequences for bovine and mouse PLP; bovine, human, chimpanzee, rat, mouse, pig, rabbit, guinea pig MBP; human and bovine collagen alpha-l(II) and bovine collagen alpha- 1(1); chicken collagen ⁇ , and human insulin are well-known and published and these antigens can be synthesized by recombinant techniques, as is well-known in the art. Fragments of these antigens can be chemically synthesized or also synthesized by recombinant techniques.
- tissue-specific antigens are commercially available: e.g., insulin, glucagon, myelin basic protein, myelin, collagen I, collagen ⁇ , proteolipid protein, etc.
- Bystander antigens can be routinely identified. Any antigen from the afflicted tissue is a potential bystander.
- the potential bystander can be fed to mammals, and spleen cells or circulating T-cells from, e.g. , the blood or cerebrospinal fluid in the case of EAE or MS, from these mammals can be removed and stimulated in vitro with the same antigen.
- T- cells elicited by stimulation can be purified and supematants can be tested for their content of TGF- 5, IL-4, IL-10, or other immunoregulatory substances.
- TGF-jS can be measured quantitatively and/or qualitatively by ELISA using preferably a suitable commercially available polyclonal or most preferably monoclonal antibody raised against TGF- (e.g. R&D Systems, Minneapolis, MN; Celtrix Pharmaceuticals, Santa Clara, CA). Miller, A. et al. , J. Immunol., 148:1106, 1992.
- a suitable commercially available polyclonal or most preferably monoclonal antibody raised against TGF- e.g. R&D Systems, Minneapolis, MN; Celtrix Pharmaceuticals, Santa Clara, CA. Miller, A. et al. , J. Immunol., 148:1106, 1992.
- another known assay for TGF- ⁇ detection can be employed, such as that described in the Examples below, using a commercially available mink lung epithelial cell line.
- T-cells can be similarly tested for secretion of IL-4 or IL-10 (antibodies for IL-4 and IL-10 are commercially available, e.g., from Pharmingen, San Diego, CA).
- Tissue-specific antigens that are not effective bystanders are those so segregated from the inflammatory locus (of autoimmune attack) so that the immunoregulatory cytokines released are too far removed from the locus of inflammation to exert a suppressive effect.
- the efficacy of mucosally induced bystander suppression can be assessed, e.g. , by: diminution in certain inflammation markers, such as the number of activated T-cell clones directed against the organ or tissue that is the target of autoimmune attack; decrease in IL-2 or IFN- ⁇ levels at the same locus; histological evaluation of the afflicted organ or tissue (e.g. by biopsy or magnetic resonance imaging); or reduction in the number and/ or severity of clinical symptoms associated with an autoimmune disease.
- certain inflammation markers such as the number of activated T-cell clones directed against the organ or tissue that is the target of autoimmune attack
- decrease in IL-2 or IFN- ⁇ levels at the same locus e.g. by histological evaluation of the afflicted organ or tissue (e.g. by biopsy or magnetic resonance imaging); or reduction in the number and/ or severity of clinical symptoms associated with an autoimmune disease.
- the tolerance induced by the bystander antigens of this invention is dose- dependent over a broad range of oral (or enteral) or inhalable dosages.
- active suppression of the clinical and histological symptoms of an autoimmune disease occurs within a specific dosage range, which, however, varies from disease to disease, mammal to mammal, and bystander antigen to bystander antigen.
- the suppressive dosage range when MBP is used as the bystander is from about 0J to about 1 mg/mouse/feeding (with feedings occurring about every other day e.g., 5-7 feedings over a 10-14-day period).
- a most preferred dosage is 0.25 mg/mouse/feeding.
- the MBP suppressive dosage range is from about 0.5 to about 2 mg/rat/feeding and the most preferred dosage is 1 mg/rat/feeding.
- An effective dosage range for humans with MS, when MBP is used as the oral tolerizer, is between about 1 and about 100, preferably between about 1 and about 20 mg MBP per day (administered every day or on alternate days for a period of time ranging from several months to several years) with the optimum being between about 7 and 10 mg per day.
- effective dosage range for humans receiving either Type I or ⁇ or Type HI collagen is between about 0.005 and about 1 mg per day.
- a preferred dosage is between about 0.005 and about .5 mg per day.
- Monitoring of the patient may be desirable in order to optimize the dosage and frequency of administration.
- the exact amount and frequency of administration to a patient may vary depending on the stage, frequency of manifestation and severity of the patient's disease and the physical condition of the patient, as is well-appreciated in the art. Such optimization is preferably effected on a case-by-case basis. Optimization of the dosage necessary for immune suppression involves no more than routine experimentation, given the guidelines disclosed herein.
- Assessment of the disease severity can be accomplished according to well- known methods depending on the type of disease. Such methods include without limitation: MS: severity and number of attacks over a period of time; progressive accumulation of disability (which can be measured, e.g., on the Expanded Disability Status Scale); number and extent of lesions in the brain (as revealed, e.g. , by magnetic resonance imaging); and frequency of autoreactive T-cells.
- MS severity and number of attacks over a period of time
- progressive accumulation of disability which can be measured, e.g., on the Expanded Disability Status Scale
- number and extent of lesions in the brain as revealed, e.g. , by magnetic resonance imaging
- frequency of autoreactive T-cells limb paralysis which can be scored as follows: 0-no disease; 1- decreased activity, limp tail; 2-mild paralysis, unsteady gait; 3- moderate paraparesis, limbs splayed apart; 4-tetraplegia; and 5-death.
- RA joint swelling, joint tenderness, morning stiffness, grip strength, joint imaging techniques.
- AUR visual acuity; number of T-cells in the eye and "cloudiness" in the eye.
- Type I Diabetes pancreatic beta cell function (assessed, e.g. , by OGTT glucose tolerance test).
- NOD Model insulitis and delay of diabetes onset.
- the total arthritis score is the sum of the scores for all paws.
- Maximum arthritis score is the highest score for an animal over the course of the disease. According to this grading method the highest arthritis score possible is 16 (4 paws X 4 score-per- paw).
- Stabilization of symptoms, under conditions wherein control patients or animals experience a worsening of symptoms, is one indicator of efficacy of a suppressive treatment. Another measure of improvement is the ability to reduce or discontinue other medications, e.g., steroids or other anti-inflammatory medications, and biologic response modifiers.
- the optimum dosage of a bystander antigen or autoantigen is one generating the maximum beneficial effect assessed as described above.
- An effective dosage causes at least a statistically or clinically significant attenuation of at least one marker, symptom or histological evidence characteristic of the disease being treated as described above.
- the dosage of bystander antigen may equal that which would have been used if the bystander antigen (or autoantigen) was administered alone, except that the combination is more effective in abating autoimmune reaction.
- methotrexate is as high as that where methotrexate is used alone
- the combination with a bystander antigen or autoantigen can result in enhanced suppressive effects.
- a sub-optimal dosage of methotrexate can be administered in order to lessen methotrexate' s toxic effects.
- the enhanced suppression achieved by the combination can, for example, be as high as that achieved by an optimal dose of methotrexate alone.
- dosages for mammals and human dosages can be determined by beginning with a relatively low dose (e.g. 1 microgram), progressively increasing it (e.g. logarithmically) and measuring the number of TGF-beta (and/or IL-4 or IL-10) secreting cells and/or assessing the number and activation of immune attack T-cells in the blood (e.g. by limiting dilution analysis and ability to proliferate) and/or assessing the disease severity, as described above.
- the optimum dosage generates the maximum amount of suppressive cytokines in the blood and/ or causing the greatest decrease in disease symptoms.
- An effective dosage causes at least a statistically or clinically significant attenuation of at least one symptom characteristic of the disease being treated.
- the maximum effective dosage of a bystander antigen can be ascertained by testing progressively higher dosages in animals and then extrapolating to humans. For example, based on the dosages given above, for rodents, the maximum effective dose of MBP for humans has been estimated between 50 and 100 mg/feeding. Similarly, the maximum effective amount of Collagen Type II for humans has been estimated at about 1 mg/day.
- the present invention can also be advantageously used to prevent the onset of an autoimmune disease in susceptible individuals at risk for an autoimmune disease.
- autoimmune diseases e.g., MS, RA, AT and AUR
- MS, RA, AT and AUR autoimmune diseases
- autoimmune diseases and tissue- or organ-specific confirmed or potential bystander antigens and autoantigens effective in the treatment of these diseases when administered in an oral or inhalable form are set forth in Table 1 below.
- Combinations of antigens listed for each individual disease can also be administered, Bystander antigens and autoantigens can also be admmistered by inhalation.
- the bystander amounts that need to be inhaled are generally smaller than those for oral administration. Effective amounts for inhalation therapy can be assessed using the same methodologies provided above.
- extracts of the relevant tissue can be used as mucosal tolerizers.
- the bystander antigen need not be purified.
- myelin which could be derived from different species
- pancreatic cell extracts have been used for Type 1 diabetes
- splenic cell extracts have been used to prevent allograft rejection (this is not an autoimmune phenomenon)
- muscle extracts have been used to treat myositis.
- administration of one or more individual antigens or fragments is preferred.
- an effective amount (determined as described above) of glucagon when treating Type 1 diabetes, an effective amount (determined as described above) of glucagon can be administered orally.
- Glucagon is specifically present in the pancreas.
- Glucagon is clearly not an autoantigen because it is not expressed in pancreatic beta cells which are destroyed in the course of Type 1 diabetes (glucagon is found exclusively in alpha cells, a different cell type).
- glucagon is a "pure" bystander: it does not appear to have any autoantigen activity. (Presumably, the bystander activity of glucagon results from its high local concentration in the pancreatic intercellular milieu due to its secretion from alpha cells.)
- Insulin has bystander activity for Type 1 diabetes. It is not at present known whether insulin is also an autoantigen, although anti-insulin autoantibodies are found in Type 1 patients. However, whatever the mechanism of action, oral, enteral or inhalable insulin preparations are effective in suppressing Type 1 diabetes and animal models therefor by preventing autoimmune destruction of pancreatic beta cells.
- Type-I, Type-II and Type-IQ collagen have activity as mucosal tolerizers. Other collagens are likely to be similarly active.
- S-antigen and IRBP and fragments thereof have bystander activity. Fragments of bystander antigens can also be employed. Useful fragments can be identified using the overlapping peptide method and T-cells from fed animals can be tested for secretion of TGF-/3, and/or IL-4 and/or IL-10, and can further be identified by subtype (CD8 + and/or CD4 + ). Mucosally administered bystander antigens elicit regulatory T-cells and thereby induce the production and/or release of TGF-/3 and/or IL-4 and IL-10.
- T-cell has been identified in mice orally tolerized against EAE as a CD4+ suppressor T- cell, and a CD8+ suppressor T-cell has been identified in rats.
- immunodominant epitopes of autoantigens e.g. MBP
- MBP immunodominant epitopes of autoantigens
- Additional such epitopes can be identified by feeding a bystander antigen to a mammal and isolating from the mammal T-cells that recognize a fragment of the antigen (and thus identifying suppressive fragments), or by identifying T-cells from a bystander fed mammal that can adoptively transfer protection to naive (not-fed) animals.
- cytokine and non-cytokine synergists can be conjoined in the treatment to enhance the effectiveness of oral tolerization with methotrexate.
- Oral and parenteral use of other cytokine synergists has been described in PCT/US95/04120, filed 04/07/95.
- Admmistration of Th2 enhancing cytokines is described in PCT application no. PCT/US95/04512, filed 04/07/95.
- IL-4 and IL-10 can be admmistered in the manner described in PCT/US95/04512.
- Non- limiting examples of non-cytokine synergists for use in the present invention include bacterial lipopolysaccharides from a wide variety of gram negative bacteria such as various subtypes of R coli and Salmonella (LPS, Sigma Chemical Co., St. Louis, MO; Difco, Detroit, MI; BIOMOL Res. Labs. , Madison, PA), Lipid A (Sigma Chemical Co. , St. Louis, MO; ICN Biochemicals, Cleveland, OH; Polysciences, Inc.
- immunoregulatory lipoproteins such as peptides covalently linked to tripalmitoyl-S- glycarylcysteinyl-seryl-serine (P 3 C55) which can be obtained as disclosed in Deres, K. et al. (Nature. 342:561-564, 1989) or "Braun's" lipoprotein from R coli which can be obtained as disclosed in Braun, V. , Biochim. Biophys.
- LPS cholera toxin ⁇ -chain
- the effective dosage range for noncytokine synergists for mammals is from about 15 ⁇ g to about 15 mg per kg weight and preferably 300 ⁇ g - 12 mg per kg weight.
- the effective dosage range for oral Type I interferon for mammals is from 1 ,000 - 150,000 units with no maximum effective dosage having been discerned.
- Ascertaining the optimum regimen for administering both the tolerizing agent and methotrexate is determined in light of the information disclosed herein and well known information concerning administration of bystander antigens, autoantigens, and methotrexate. Routine variation of dosages, combinations, and duration of treatment is performed under circumstances wherein the severity of autoimmune reaction can be measured. Useful dosage and administration parameters are those that result in reduction in autoimmune reaction, including a decrease in number of autoreactive T-cells, or in the occurrence or severity of at least one clinical or histological symptom of the disease.
- the tolerizing agent is preferably administered within 24 hours of administration of methotrexate. More preferably, it is administered at the same time as methotrexate. Most preferably, both are admmistered in a combined oral formulation.
- Methotrexate for use in the invention is commonly commercially available in both oral and parenteral dosage forms. Alternately, methotrexate is conventionally formed in an oral or parenteral dosage form, using carriers and other agents as further described below.
- Each oral (or enteral) formulation according to the present invention may comprise inert constituents including pharmaceutically acceptable carriers , diluents , fillers , solubilizing or emulsifying agents, and salts, as is well-known in the art.
- tablets may be formulated in accordance with conventional procedures employing solid carriers well-known in the art.
- Capsules employed in the present invention may be made from any pharmaceutically acceptable material, such as gelatin, or cellulose derivatives.
- Sustained release oral delivery systems and/or enteric coatings for orally administered dosage forms are also contemplated, such as those described in U.S. Patent No. 4,704,295, issued November 3, 1987; U.S. Patent No. 4,556,552, issued December 3, 1985; U.S. Patent No. 4,309,404, issued January 5, 1982; and U.S. Patent No. 4,309,406, issued January 5, 1982.
- solid carriers examples include starch, sugar, bentonite, silica, and other commonly used carriers.
- carriers and diluents which may be used in the formulations of the present invention include saline, syrup, dextrose, and water.
- formulations for tolerizing agents that are administered by inhalation are provided in PCT/US90/07455, filed 12/17/90.
- the pharmaceutical formulations for admmistration by inhalation of the present invention may include, as optional ingredients, pharmaceutically acceptable carriers, diluents, solubilizing and emulsifying agents, and salts of the type that are well-known in the art.
- pharmaceutically acceptable carriers such as pharmaceutically acceptable saline solutions, such as physiologically buffered saline solutions, and water.
- the route of administration of tolerizing antigens according to this alternate embodiment of the present invention is in an aerosol or inhaled form.
- the antigens can be administered as dry powder particles or as an atomized aqueous solution suspended in a carrier gas (e.g. air or N 2 ).
- a carrier gas e.g. air or N 2
- Preferred aerosol pharmaceutical formulations may comprise for example, a physiologically-acceptable buffered saline solution containing between about 1 mg and about 300 mg of the antigens.
- Dry aerosol in the form of finely divided solid particles of tolerizing antigens that are not dissolved or suspended in a liquid are also useful in the practice of the present invention.
- the tolerizing antigens may be in the form of dusting powders and comprise finely divided particles having an average particle size of between about 1 and 5 microns, preferably between 2 and 3 microns.
- Finely divided particles may be prepared by pulverization and screen filtration using techniques well known in the art.
- the particles may be administered by inhaling a predetermined quantity of the finely divided material, which can be in the form of a powder.
- the carriers and/or diluents that are useful in the by-inhalation pharmaceutical formulations include water and physiologically- acceptable buffered saline solutions such as phosphate buffered saline solutions pH 7.0- 8.0. Additional non-limiting examples of suitable carriers or diluents for use in by- inhalation pharmaceutical formulations or dosage forms of the present invention are disclosed in U.S. Patent Nos. 4,659,696, issued April 21, 1987, 4,863,720, issued September 5, 1989 and 4,698,332, issued October 6, 1987.
- the pharmaceutical formulations of the present invention may be administered in the form of an aerosol spray using for example, a nebulizer such as those described in U.S. Patent Nos. 4,624,251 issued November 25, 1986; 3,703,173 issued November 21, 1972; 3,561,444 issued February 9, 1971 and 4,635,627 issued January 13, 1971.
- the aerosol material is inhaled by the subject to be treated.
- Aerosol delivery systems such as the pressurized metered dose inhaler (MDI) and the dry powder inhaler as disclosed in Newman, S.P. in Aerosols and the Lung. Clarke, S.W. and Davia, D. eds. pp. 197-224, Butterworths, London, England, 1984, can be used when practicing the present invention.
- Aerosol delivery systems of the type disclosed herein are available from numerous commercial sources including Fisons Corporation (Bedford, MA), Schering Corp. (Kenilworth, NJ) and American Pharmoseal Co. (Valencia, CA).
- EXAMPLE 1 Suppression of EAE in Rats with a Combination of an Optimal Dose of Methotrexate and a Tolerizing Agent
- Guinea pig MBP was purified from brain tissue by the modified method of Deibler et al. (Prep. Biochem. 2:139, 1972). Protein content and purity were monitored by gel electrophoresis and amino acid analysis. Methotrexate was obtained from Roxane Lab. Inc. (Columbus, OH). Methotrexate tablets (2.5 mg) were mixed with buffer (H 2 O:PBS in a 1:1 ratio) to obtain a concentration of 2.5 mg methotrexate/ml buffer.
- Clinical evaluation Animals were evaluated in a blind fashion every day for evidence of EAE. Clinical severity of EAE was scored as follows: 0, no disease; 1 limp tail; 2, hind limb paralysis; 3, hind limb paraplegia, incontinence; 4, tetraplegia; and 5 death. "MMCS” refers to the mean maximal clinical score. Duration of disease was measured by counting the total number of days from disease onset until complete recovery (or death) for each animal.
- methotrexate was administered by itself, and in combination with 1 mg of GP-MBP (guinea pig MBP).
- the 80 ⁇ g of methotrexate administered at a frequency of three times a week corresponds to the optimal dosage of methotrexate admmistered to humans, when adjusted for weight.
- the recommended dose for a 60 Kg person is 10 mg of methotrexate per week.
- this corresponds to admmistration to a 212.2g rat of 238 ⁇ g methotrexate per week, or 80 ⁇ g methotrexate three times per week.
- MBP achieved greater suppression than either compound administered by itself.
- the suppression achieved with the combination was substantially greater than with either substance alone.
- EXAMPLE 2 Suppression of EAE in Rats with a Combination of a Sub-Optimal Dose of Methotrexate and Tolerizing Agent
- Example 2 The procedures described in Example 1 were followed, for the protocol shown below. Sub-optimal dosages of 40 ⁇ g and 20 / ⁇ g were admmistered in combination with 1 mg of MBP over a period of 14 days. An optimal dosage of 80 ⁇ g was also administered.
- % TOLERANCE MMCS (CONTROL) - MMCS (TEST X 100
- FIGS 1-5 show clinical data from this experiment for 20 days after immunization with MBP in Complete Freund's Adjuvant.
- Figure 1 shows the results of administration of methotrexate alone.
- the graph shows a rebound effect associated with methotrexate administration, wherein, following the highest degree of suppression, at day 18, the clinical symptoms of the disease reappear.
- Figure 2 shows the effects on clinical scores of administering an optimal dose of methotrexate compared with an optimal dose of MBP. A rebound effect is seen at day 20 for rats administered methotrexate, but not for rats administered MBP.
- Figure 3 shows the effects on clinical scores of admimstering an optimal dose of methotrexate as compared with a combination of an optimal dose of methotrexate and an optimal dose of MBP. Adding MBP to the optimal dose methotrexate does not interfere with methotrexate' s effects. Nor does methotrexate interfere with MBP's effect in eliminating the rebound at day 20. Thus, the effect obtained admimstering the combination of MBP and even an optimal dose of methotrexate is superior to that seen from administering either agent by itself.
- Figure 4 shows the results of admimstering MBP alone and a sub-optimal dose of 40 ⁇ g of methotrexate alone as compared with administering a combination of the two.
- the combination achieves greater suppression than that achieved with either alone, and avoids the rebound effect seen with methotrexate alone.
- the degree of suppression is essentially the same as that observed with the an optimal dose of methotrexate alone.
- Figure 5 shows the results of administering MBP alone and a sub-optimal dose of 20 ⁇ g of methotrexate alone as compared with administering a combination of the two.
- the combination achieves greater suppression than that achieved with either alone.
- the degree of suppression is similar to that observed with an optimal dose of methotrexate alone.
- a lower dose of methotrexate can be administered than is optimal, but, as a result of the combination with MBP, a suppressive effect is achieved that is similar to that of an optimal dose of methotrexate alone.
- the combination eliminates the rebound effect associated with methotrexate admmistration alone.
- DBA/J1 mice were orally dosed once a day for 5 consecutive days with type ⁇ collagen (300 ⁇ g in 0.25 ml), methotrexate (10 ⁇ g in 0.25 ml), a combination of the two, or with a control solution of 0J N acetic acid (0.25 ml).
- the type ⁇ collagen was chicken sterna type ⁇ collagen (1.2 mg/ml) (Sigma Chemical Co., St. Louis, MO).
- the methotrexate was obtained as 2.5 mg tablets (Roxane Lab. Inc.). The tablets were mixed with 0J normal acetic acid to form a 2.5 mg/ml solution.
- the amount of methotrexate administered was determined based on an optimal dosage to a 60 Kg human of lOmg/week, using the converting factor of 12 for mice (Chemotherapy National Cancer Institute), and based on an average weight of 26 g per mouse.
- each animal was injected intradermaUy into its shaved back with 0J ml of an emulsion containing 100 ⁇ g of type II collagen and 100 ⁇ g of Mycobacterium butyricum.
- All mice were boosted with an intraperitoneal injection of 100 ⁇ g of type ⁇ collagen in 0J N acetic acid.
- Animals were monitored for onset of arthritis for 60 days. Beginning on day +10, animals are scored for signs of arthritis on a scale of 0 to 4. The arthritis score for each animal was the sum of the score for each of the four paws.
- Serum free culture supematants are collected from cells from test animals. See, for example, Kehri, et al. J. Exp.Med.163: 1037-1050, 1986; and Wahl, et al. J.ImmunolJ45: 2514-2419,1990. Briefly, modulator cells are first cultured for 8 hours with the antigen (50 ⁇ l/ml) in proliferation medium. Thereafter cells are washed three times and resuspended in serum-free medium for the remainder of the 72 hour culture, supematants collected, then frozen until assayed.
- TGF-/3 content and isoform type in supematants is performed using a mink lung epithelial cell line (American Type Culture Collection, Bethesda, MD #CCL-64) according to Danielpour et al. (Danielpour, D., et al. J. Cell. Physiol. 138: 79-86,1989).), and confirmed by a Sandwich Enzyme Linked Immunosorbent Assay (SEOSA) assay as previously described (Danielpour et al. Growth Factors 2: 61-71,1989). The percent active TGF-/5 is determined by assay without prior acid activation of the samples.
- SEOSA Sandwich Enzyme Linked Immunosorbent Assay
- This assay can be adapted to test any antigen which is a candidate for use as an inducer of bystander suppression. Those antigens, antigen fragments and/or amounts of antigen which produce the highest concentration of TGF- ⁇ as measured by this assay are suitable for use in the treatment method of the present invention.
- a transwell culture system described below, can be used to indicate the level of TGF- 5 which is being produced. This culture system measures the production of TGF-/3 as a function of suppression of cell proliferation.
- IL-4 and/or IL-10 in culture supematants of antigen- stimulated cells can also serve as an indicator that the antigen is suitable for use as an inducer of bystander suppression.
- IL-4, IL-10 (and TGF- ) can be assayed by EOSA using commercially available antibodies to each polypeptide as described in Chen, Y. et al., Science. 1994, supra.
- modulator cells are added in the lower well together with responder cells, and in these instances modulator cells are irradiated (1,250 rad) immediately before being placed in culture.
- Proliferation media consisted of RPMI 1640 (Gibco Laboratories, Grand Island, NY) supplemented with 2 x 10 5 M 2-mercaptoethanol, 1 % sodium pyravate, 1 % penicillin and streptomycin, 1 % glutamine, 1 % HEPES buffer, 1 % nonessential amino acids, and 1 % autologous serum. Each transwell is performed in quadruplicate. The transwells are incubated at 37°C in a humidified 6% CO 2 and 94% air atmosphere for 72 hours.
- each lower well is pulsed with 4 ⁇ Ci of pETJthymidine and at 72 hours split and reseeded to three wells in a round-bottomed 96-well plate (Costar) for harvesting onto fiberglass filters and counting using standard liquid scintillation techniques.
- Percent suppression 100 x (1 - ⁇ cpm responders cultured with modula- tors/ ⁇ cpm of responders).
- Figures 6-8 show the swollen joint count measured during the period of the study.
- the group of patients with exacerbated symptoms at week 8 exhibited increased swollen joint count at that time.
- this group of patients exhibited a decrease in the number of swollen joints, and after eight weeks of combination therapy (which corresponds to the 16 week mark in Figure 6) exhibited a greater decrease in swollen joints (from their baseline number) than patients receiving only type JJ collagen.
- Figure 7 with respect to tender joint count followed a similar pattern.
- Figure 8 was higher for patients receiving combination therapy than for those receiving only oral type ⁇ collagen.
- the Paulus response for the patients receiving the colloral- methotrexate combination was calculated from the time that methotrexate was combined with type JJ collagen at week 8.
Abstract
L'invention concerne une combinaison d'un antigène de voisinage susceptible d'être administré par voie muqueuse et d'un méthotrexate susceptible d'être administré par voie parentérale, entérale ou orale. Cette combinaison est utilisée pour mettre en oeuvre une formulation pharmaceutique et pour traiter ou prévenir des maladies auto-immunes. Les quantités d'antigène de voisinage et de méthotrexate sont efficaces en combinaison pour supprimer une réponse auto-immune associée à la maladie auto-immune.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU66488/98A AU6648898A (en) | 1997-01-24 | 1998-01-26 | Treatment of autoimmune disease using tolerization in combination with methotrexate |
EP98908452A EP0994717A4 (fr) | 1997-01-24 | 1998-01-26 | Traitement des maladies auto-immunes a l'aide d'une tolerance induite en combinaison avec du methotrexate |
JP53225298A JP2001511134A (ja) | 1997-01-24 | 1998-01-26 | メトトレキサートと組合せる耐性化を用いる自己免疫疾患の治療 |
CA002278152A CA2278152A1 (fr) | 1997-01-24 | 1998-01-26 | Traitement des maladies auto-immunes a l'aide d'une tolerance induite en combinaison avec du methotrexate |
BR9807112-2A BR9807112A (pt) | 1997-01-24 | 1998-01-26 | Composição, formulação farmacêutica, combinação e uso relacionados ao tratamento de doenças autoimunes utilizando antìgeno ou agente tolerante em combinação com metotrexato |
HU0001960A HUP0001960A2 (hu) | 1997-01-24 | 1998-01-26 | Metotrexát kombináció autoimmun tünetek befolyásolására |
IL13102598A IL131025A0 (en) | 1997-01-24 | 1998-01-26 | Treatment of autoimmune disease using tolerization in combination with methotrexate |
NO993600A NO993600L (no) | 1997-01-24 | 1999-07-23 | Behandling av autoimmun sykdom ved Õ bruke "tolerization" i kombinasjon med metotreksat |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3672297P | 1997-01-24 | 1997-01-24 | |
US60/036,722 | 1997-01-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998032451A1 WO1998032451A1 (fr) | 1998-07-30 |
WO1998032451A9 true WO1998032451A9 (fr) | 1998-12-30 |
Family
ID=21890248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/001648 WO1998032451A1 (fr) | 1997-01-24 | 1998-01-26 | Traitement des maladies auto-immunes a l'aide d'une tolerance induite en combinaison avec du methotrexate |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0994717A4 (fr) |
JP (1) | JP2001511134A (fr) |
KR (1) | KR20000070460A (fr) |
AU (1) | AU6648898A (fr) |
BR (1) | BR9807112A (fr) |
CA (1) | CA2278152A1 (fr) |
HU (1) | HUP0001960A2 (fr) |
IL (1) | IL131025A0 (fr) |
NO (1) | NO993600L (fr) |
WO (1) | WO1998032451A1 (fr) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9333309B2 (en) | 2002-02-11 | 2016-05-10 | Antares Pharma, Inc. | Intradermal injector |
US9364611B2 (en) | 2012-05-07 | 2016-06-14 | Antares Pharma, Inc. | Needle assisted jet injection device having reduced trigger force |
US9393367B2 (en) | 2013-03-12 | 2016-07-19 | Antares Pharma, Inc. | Prefilled syringes and kits thereof |
US9446195B2 (en) | 2011-07-15 | 2016-09-20 | Antares Pharma, Inc. | Injection device with cammed ram assembly |
US9486583B2 (en) | 2012-03-06 | 2016-11-08 | Antares Pharma, Inc. | Prefilled syringe with breakaway force feature |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1850892B2 (fr) | 2005-01-24 | 2023-04-19 | Antares Pharma, Inc. | Injecteur a seringue preremplie assiste d'une aiguille |
GB0523576D0 (en) * | 2005-11-18 | 2005-12-28 | Theradeas Ltd | Drug composition and its use in therapy |
WO2007131025A1 (fr) | 2006-05-03 | 2007-11-15 | Antares Pharma, Inc. | Injecteur à dosage réglable |
WO2007131013A1 (fr) | 2006-05-03 | 2007-11-15 | Antares Pharma, Inc. | Injecteur de reconstitution à deux étages |
JP5731829B2 (ja) | 2008-03-10 | 2015-06-10 | アンタレス・ファーマ・インコーポレーテッド | 注射器安全装置 |
AU2009279719B2 (en) | 2008-08-05 | 2015-07-23 | Antares Pharma, Inc. | Multiple dosage injector |
JP5732039B2 (ja) | 2009-03-20 | 2015-06-10 | アンタレス・ファーマ・インコーポレーテッド | 危険有害性薬剤の注入システム |
WO2011159821A1 (fr) | 2010-06-16 | 2011-12-22 | Bruce Chandler May | Utilisation de la lévocétirizine et du montélukast dans le traitement de la grippe, du rhume et d'une inflammation |
US9220660B2 (en) | 2011-07-15 | 2015-12-29 | Antares Pharma, Inc. | Liquid-transfer adapter beveled spike |
EP4186545A1 (fr) | 2012-04-06 | 2023-05-31 | Antares Pharma, Inc. | Administration par injection par jet assistée par aiguille de compositions de testostérone |
EP4349383A2 (fr) | 2013-02-11 | 2024-04-10 | Antares Pharma, Inc. | Dispositif d'injection par jet assisté par aiguille ayant une force de déclenchement réduite |
JP6030803B2 (ja) | 2013-03-11 | 2016-11-24 | アンタレス・ファーマ・インコーポレーテッド | ピニオンシステムを有する用量注射器 |
EP2969010B1 (fr) * | 2013-03-13 | 2017-10-11 | Inflammatory Response Research, Inc. | Utilisation de levocetirizine et de montelukast dans le traitement des maladies auto-immunes |
EP2969002B8 (fr) | 2013-03-13 | 2018-02-21 | Inflammatory Response Research, Inc. | Utilisation de levocetirizine et montelukast dans le traitement de blessure traumatique |
CN105263579B (zh) | 2013-03-13 | 2020-01-10 | 炎症反应研究公司 | 左西替利嗪和孟鲁司特在治疗血管炎中的用途 |
WO2016044095A1 (fr) | 2014-09-15 | 2016-03-24 | Inflammatory Response Research, Inc. | Lévocétirizine et montélukast dans le traitement de troubles médiés par une inflammation |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE258065T1 (de) * | 1987-06-24 | 2004-02-15 | Brigham & Womens Hospital | Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen |
US5571500A (en) * | 1987-06-24 | 1996-11-05 | Autoimmune, Inc. | Treatment of autoimmune diseases through administration by inhalation of autoantigens |
US5571499A (en) * | 1987-06-24 | 1996-11-05 | Autoimmune, Inc. | Treatment of autoimmune diseases by aerosol administration of autoantigens |
AU650065B2 (en) * | 1990-09-06 | 1994-06-09 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur | Inhibitor of lymphocyte response and immune-related disease |
HU220357B (hu) * | 1992-02-28 | 2001-12-28 | Autoimmune Inc. | Eljárás és készítmények autoimmun betegségek kezelésére bystander antigén alkalmazásával |
WO1996040235A1 (fr) * | 1995-06-07 | 1996-12-19 | Nexstar Pharmaceuticals, Inc. | Procede d'utilisation de superantigenes pour cibler des sous-populations de lymphocytes t |
EP0834321B1 (fr) * | 1995-06-13 | 2003-05-02 | Nippon Meat Packers, Inc. | Medicament a administration par voie orale contre la polyarthrite rhumatoide et aliment fonctionnel |
-
1998
- 1998-01-26 BR BR9807112-2A patent/BR9807112A/pt not_active Application Discontinuation
- 1998-01-26 IL IL13102598A patent/IL131025A0/xx unknown
- 1998-01-26 WO PCT/US1998/001648 patent/WO1998032451A1/fr not_active Application Discontinuation
- 1998-01-26 JP JP53225298A patent/JP2001511134A/ja active Pending
- 1998-01-26 HU HU0001960A patent/HUP0001960A2/hu unknown
- 1998-01-26 EP EP98908452A patent/EP0994717A4/fr not_active Withdrawn
- 1998-01-26 AU AU66488/98A patent/AU6648898A/en not_active Abandoned
- 1998-01-26 KR KR1019997006698A patent/KR20000070460A/ko not_active Application Discontinuation
- 1998-01-26 CA CA002278152A patent/CA2278152A1/fr not_active Abandoned
-
1999
- 1999-07-23 NO NO993600A patent/NO993600L/no unknown
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9333309B2 (en) | 2002-02-11 | 2016-05-10 | Antares Pharma, Inc. | Intradermal injector |
US9446195B2 (en) | 2011-07-15 | 2016-09-20 | Antares Pharma, Inc. | Injection device with cammed ram assembly |
US9486583B2 (en) | 2012-03-06 | 2016-11-08 | Antares Pharma, Inc. | Prefilled syringe with breakaway force feature |
US9364611B2 (en) | 2012-05-07 | 2016-06-14 | Antares Pharma, Inc. | Needle assisted jet injection device having reduced trigger force |
US9364610B2 (en) | 2012-05-07 | 2016-06-14 | Antares Pharma, Inc. | Injection device with cammed ram assembly |
US9393367B2 (en) | 2013-03-12 | 2016-07-19 | Antares Pharma, Inc. | Prefilled syringes and kits thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5935577A (en) | Treatment of autoimmune disease using tolerization in combination with methotrexate | |
EP0627933B1 (fr) | Suppression de maladies auto-immunes par des antigenes en attente | |
US6645504B1 (en) | Bystander suppression of type I diabetes by oral administration of glucagon | |
WO1998032451A9 (fr) | Traitement des maladies auto-immunes a l'aide d'une tolerance induite en combinaison avec du methotrexate | |
EP0994717A1 (fr) | Traitement des maladies auto-immunes a l'aide d'une tolerance induite en combinaison avec du methotrexate | |
Miller et al. | Epitopes of myelin basic protein that trigger TGF-beta release after oral tolerization are distinct from encephalitogenic epitopes and mediate epitope-driven bystander suppression. | |
AU642693B2 (en) | Improved treatment of autoimmune diseases by aerosol administration of auto antigens | |
US5783188A (en) | Method of treating rheumatoid arthritis with type collagen peptide fragments containing repeating sequences | |
AU9023791A (en) | Treatment of autoimmune diseases by oral administration of autoantigens | |
AU695883B2 (en) | Treatment of autoimmune disease using oral tolerization and/or Th2-enhancing cytokines | |
AU686797B2 (en) | Treatment of autoimmune disease using oral tolerization and/or type I interferon | |
US20010007758A1 (en) | Treatment of multiple sclerosis using COP-1 and Th2-enhancing cytokines | |
US20040115217A1 (en) | Bystander suppression of autoimmune diseases | |
WO1994004121A1 (fr) | Suppression par un antigene tiers d'une maladie neurologique associee a un retrovirus | |
JP2001502306A (ja) | インシュリン依存性糖尿病の処置方法および組成物 |